Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Am J Transplant. 2021 Nov;21(11):3785-3789. doi: 10.1111/ajt.16753. Epub 2021 Jul 19.
The impact of COVID-19 vaccination on the alloimmunity of transplant candidates is unknown. We report a case of positive B cell flow cytometry crossmatch in a patient waiting for second kidney transplantation, 37 days after receiving the COVID-19 vaccine. The preliminary crossmatch, using sample collected before COVID-19 vaccination, was negative. The antibodies to mismatched donor HLA-DR7 were detected only with multi-antigen beads but not with single-antigen beads, excluding possible prozone effects in solid-phase antibody assays. The crossmatches were positive with HLA-DR7-positive surrogates (n = 2) while negative with HLA-DR7-negative surrogates (n = 3), which confirms the HLA-DR7 alloreactivity. The antigen configurations on B lymphocytes are similar to that on the multi-antigen beads while distinct from the single-antigen beads. HLA-DR7 was the repeating mismatched antigen with the failing first kidney allograft. The newly emerged antibody to HLA-DR7 probably is the consequence of bystander activation of memory response by the COVID-19 vaccination. This case highlights the importance of verifying allo-sensitization history and utilizing multiple assays, including cell-based crossmatch and solid-phase assays with multi-antigens. COVID-19 immunization may deserve special attention when assessing the immunological risk before and after organ transplantation.
COVID-19 疫苗接种对移植候选者同种免疫的影响尚不清楚。我们报告了一例在接受 COVID-19 疫苗接种 37 天后等待第二次肾移植的患者中出现 B 细胞流式细胞交叉配型阳性的情况。使用 COVID-19 疫苗接种前采集的样本进行的初步交叉配型为阴性。仅使用多抗原珠检测到与错配供体 HLA-DR7 的抗体,而单抗原珠则未检测到,排除固相抗体检测中可能存在的前带效应。与 HLA-DR7 阳性替代物(n=2)的交叉配型阳性,而与 HLA-DR7 阴性替代物(n=3)的交叉配型阴性,这证实了 HLA-DR7 的同种反应性。B 淋巴细胞上的抗原构型与多抗原珠上的相似,而与单抗原珠上的不同。HLA-DR7 是与首次失败的肾移植同种异体反应的重复错配抗原。新出现的针对 HLA-DR7 的抗体可能是 COVID-19 疫苗接种导致记忆反应的旁观者激活的结果。该病例强调了在评估器官移植前后的免疫风险时,验证同种致敏史和利用多种检测方法(包括细胞交叉配型和多抗原固相检测)的重要性。在评估器官移植前后的免疫风险时,COVID-19 免疫接种可能值得特别关注。